GENFIT Highlights Data from Clinical Studies of Nangibotide, Supporting Its Advancement into ACLF with Phase 2 Data Expected in 2027
Lille (France), Cambridge (Massachusetts, United States), November 9, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, yesterday unveiled an in-depth review of nangibotide, its new lead asset in acute-on-chronic liver failure (ACLF), during a scientific event gathering leading ACLF experts in Denver during AASLD The Liver Meeting®.
Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.comSummary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.